KDR and neoplasm: Lenvatinib is another oral small molecule multikinase inhibitor that selectively inhibits tyrosine kinases (e.g., VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptor (FGFR1, FGFR2, FGFR3, FGFR4), PDGFR2, FGF and RET to suppress tumor angiogenesis and growth [10].